GTx-758 to be tested at lower doses in men with mCRPC

According to a media release issued yesterday by GTx, Inc., the U.S. Food & Drug Administration is allowing the company to proceed with a proposed, open-label, Phase II clinical trial of Capesaris® — also known as GTX-758 — in the treatment of men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

GTx forced to stop development of Capesaris (GTx-758)

The US Food & Drug Administration (FDA) has advised GTx to stop development of GTx-758 (also known as Capesaris), its oral drug intended for the treatment of men with advanced prostate cancer, after it became apparent that there was an increase in risk for blood clots in men taking active drug compared to those being treated with a placebo. … READ MORE …

GTx initiates Phase IIb trial of Capesaris for advanced prostate cancer

GTx, Inc. has announced the initiation of  a randomized Phase IIb trial of their selective estrogen receptor α agonist Capsesaris™ (previously known as GTx-758) versus leuprolide acetate (Lupron Depot®) as first-line androgen deprivation therapy for progressive and advanced forms of prostate cancer. … READ MORE …

GTx-758 to enter Phase IIb clinical trial

GTx, Inc. has announced this morning that the company is planning a Phase IIb clinical trial of its oral, selective estrogen receptor agonist (GTx-758, also known as  Capesaris™) as a potential first-line treatment for advanced prostate cancer. … READ MORE …

GTx says selective estrogen receptor agonist induces medical castration

According to a Reuters report based on a recent media release from GTx, the investigational agent GTx-758 is able to induce temporary medical castration in healthy volunteers, making this agent yet another possible candidate for the hormonal management of progressive prostate cancer. … READ MORE …

GTX-758 in treatment of prostate cancer

GTx has announced a second Phase I clinical trial evaluating GTx-758, an oral luteinizing hormone (LH) inhibitor (not an LHRH agonist or an LHRH antagonist), for first-line treatment of advanced prostate cancer. … READ MORE …

Trials start for new form of androgen deprivation therapy

Volunteers are now receiving doses of GTx’s luteinizing hormone (LH) inhibitor — GTx-758 — in a Phase I clinical trial. … READ MORE …